Kintor CEO Boosts Stake as Company Doubles Down on Dermatology and Cosmetic Expansion

Kintor Pharmaceutical Ltd ( (HK:9939) ) has provided an update.

Kintor Pharmaceutical Limited announced that its chairman, executive director and CEO, Dr. Youzhi Tong, has increased his stake in the company by purchasing 4.7 million shares on the open market for approximately HK$10.82 million, representing about 0.94% of the company’s issued share capital, while maintaining sufficient public float. Management framed the move as a strong vote of confidence in Kintor’s long-term growth prospects and commercialization transition, particularly for its innovative topical dermatology pipeline in hair loss and hair regrowth, and said the Group will continue to advance key drug candidates, strengthen the KOSHINÉ brand globally, and accelerate the registration and global commercialization of cosmetic ingredient KT-939, underscoring its strategic focus on dermatology and functional cosmetics markets.

The most recent analyst rating on (HK:9939) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Kintor Pharmaceutical Ltd stock, see the HK:9939 Stock Forecast page.

More about Kintor Pharmaceutical Ltd

Kintor Pharmaceutical Limited is a Cayman Islands–incorporated biopharmaceutical company focused on dermatology, developing innovative topical drugs with a particular emphasis on anti-hair loss and hair regrowth therapies. The Group is advancing core dermatology candidates KX-826 and GT20029 through clinical trials, while also building the global presence of its functional cosmetics brand KOSHINÉ and expanding the cosmetic raw material KT-939 in China and international markets through collaborations with distributors, brand owners and manufacturers.

Average Trading Volume: 1,812,596

Technical Sentiment Signal: Buy

Current Market Cap: HK$1.39B

For detailed information about 9939 stock, go to TipRanks’ Stock Analysis page.